LWBK1006-09 LWW-Govindan-Review December 12, 2011 18:51
Chapter 9•Principles of Immunotherapy 113Answer 9.19. The answer is A.
The gene product of PRAME is overexpressed in melanoma, whereas
the gene product of FGF-5 is over-expressed in renal cell carcinomas,
prostate cancer, and breast cancer. CDK4 is a mutated antigens expressed
in melanoma, whereas the gene product of MART-1 is a melanocyte dif-
ferentiation antigen expressed in melanoma.Answer 9.20. The answer is A.
The response rate of high-dose IL-2 therapy is 15% to 20% in melanoma
and renal cell carcinoma. Almost half of the responses are complete,
response durations can be substantial, lasting for over 10 years. High-dose
IL-2 therapy is associated with significant toxicity: hypotension, cardiac
arrhythmias, metabolic acidosis, fever, nausea and vomiting, dyspnea,
edema, renal failure, neurotoxicity, and dermatologic complications.Answer 9.21. The answer is C.
Because of the activation and proliferation of T-cells achieved by inhi-
bition of CTLA-4, ipilimumab is associated with many immune-
mediated adverse reactions that can be fatal. Common immune-related
reactions include enterocolitis, hepatitis, dermatitis, neuropathy, and
endocrinopathies including hypopituitarism, adrenal insufficiency, hypog-
onadism, and hypothyroidism.Answer 9.22. The answer is C.
Sipuleucel-T is formulated from CD54+cells that are activated with PAP-
GM-CSF ex vivo and then infused into patients with prostate cancer in
order to induce an immune response targeted against PAP.